(a + b) SPF C57BL/6 WT mice aged 6 to 8 weeks were administered 3.5% DSS in drinking water at day 0. Mice were additionally treated with EcN (DSS + EcN), MG1655 (DSS + MG1655), or MPK (DSS + MPK) resuspended in DSS-containing drinking water at 108 bacteria mL−1. (a) Change in body weight relative to start of DSS administration at day 0. (b) Left panel: HE-stained colonic sections at day 7 after start of DSS administration. Right panel: HCS at day 7. (c + d) SPF C57BL/6 WT mice aged 6 to 8 weeks were administered 3.5% DSS in drinking water at day 0. Mice were additionally treated with EcN (DSS + EcN) or an EcNΔfliC deletion mutant (DSS + EcNΔfliC) resuspended in DSS-containing drinking water at 108 bacteria mL−1. (c) Change in body weight relative to start of DSS administration at day 0. (d) Left panel: HE-stained colonic sections at day 7 after start of DSS administration. Right panel: HCS at day 7. (e) SPF C57BL/6 WT mice and SPF Tlr5−/− mice aged 6 to 8 weeks were administered 3.5% DSS in drinking water at day 0. Mice were additionally treated with EcN (DSS + EcN) or an EcNΔfliC deletion mutant (DSS + EcNΔfliC) resuspended in DSS-containing drinking water at 108 bacteria mL−1. Left panel: HE-stained colonic sections at day 7 after start of DSS administration. Right panel: HCS at day 7. Statistics: (a), (b), (c), (e), one-way ANOVA with Tukey multiple comparison test; (d) Kruskal–Wallis test with multiple comparisons. p-values < 0.05 are considered to represent statistical significance. (a–e) The data underlying this figure can be found in S1 Data. DSS, dextran sodium sulphate; EcN, E. coli Nissle 1917; fliC, flagellin; HCS, histological colitis score; HE, hematoxylin–eosin; MG1655, E. coli K12 MG1655; MPK, E. coli mpk; SPF, specific-pathogen–free; TLR, Toll-like receptor; WT, wild type.